A detailed history of China Universal Asset Management Co., Ltd. transactions in Cure Vac N.V. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 43,019 shares of CVAC stock, worth $141,532. This represents 0.02% of its overall portfolio holdings.

Number of Shares
43,019
Previous 43,019 -0.0%
Holding current value
$141,532
Previous $130,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$2.94 - $4.34 $50,368 - $74,352
17,132 Added 66.18%
43,019 $130,000
Q4 2023

May 21, 2024

SELL
$3.96 - $6.41 $67,842 - $109,816
-17,132 Reduced 39.82%
25,887 $108,000
Q4 2023

Jan 23, 2024

BUY
$3.96 - $6.41 $79,790 - $129,155
20,149 Added 351.15%
25,887 $109,000
Q3 2023

May 21, 2024

BUY
$6.5 - $10.77 $18,226 - $30,199
2,804 Added 95.57%
5,738 $39,000
Q3 2023

Oct 30, 2023

BUY
$6.5 - $10.77 $18,226 - $30,199
2,804 Added 95.57%
5,738 $39,000
Q2 2023

May 21, 2024

SELL
$6.69 - $12.25 $495 - $906
-74 Reduced 2.46%
2,934 $30,000
Q2 2023

Jul 27, 2023

SELL
$6.69 - $12.25 $495 - $906
-74 Reduced 2.46%
2,934 $31,000
Q1 2023

May 21, 2024

BUY
$6.38 - $12.5 $6,858 - $13,437
1,075 Added 55.61%
3,008 $20,000
Q1 2023

Apr 27, 2023

BUY
$6.38 - $12.5 $6,858 - $13,437
1,075 Added 55.61%
3,008 $21,000
Q4 2022

May 21, 2024

SELL
$5.75 - $8.5 $236,244 - $349,231
-41,086 Reduced 95.51%
1,933 $11,000
Q4 2022

Jan 31, 2023

BUY
$5.75 - $8.5 $1,017 - $1,504
177 Added 10.08%
1,933 $12,000
Q3 2022

Oct 21, 2022

BUY
$7.48 - $15.24 $13,134 - $26,761
1,756 New
1,756 $14,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $617M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.